# ADC Therapeutics SA ADC Therapeutics SA is an Asset Manager based in Epalinges, Switzerland. ## Overview - **Organization type:** Asset Manager - **Headquarters:** Epalinges, Switzerland - **Region:** Europe - **Address:** Lausanne, Switzerland - **Founded:** 2011 - **Assets under management:** Undisclosed - **Website:** adctherapeutics.com ## Regulatory record - **Reports private funds:** No ## About ADC Therapeutics launched in 2011 with backing from Auven Therapeutics, a private equity firm that incubated early-stage drug development assets. Co-founders Chris Martin and Michael Forer structured the company around an exclusive antibody-drug conjugate platform licensed from Spirogen, the UK biotech later acquired by AstraZeneca. The firm listed on the New York Stock Exchange in May 2020, raising roughly $233 million to advance a pipeline of blood cancer and solid tumor programs. The firm's development engine centers on pyrrolobenzodiazepine dimer technology, a warhead class that cross-links tumor DNA more durably than earlier chemotherapy agents. Beyond Zynlonta, which secured accelerated US approval in April 2021 for relapsed large B-cell lymphoma, the pipeline includes ADCT-601 targeting AXL-expressing solid tumors and Zynlonta combination trials with rituximab in earlier lines of follicular lymphoma. The company also holds a commercial operation in New Jersey that markets Zynlonta directly to US oncologists. The geographic footprint spans US commercialization, Swiss R&D headquarters, and a UK manufacturing subsidiary. Named development partners over time have included Swedish Orphan Biovitrum for ex-US rights to Zynlonta and Overland ADCT BioPharma for a China-focused joint venture. Headcount is not publicly updated in real time, but the firm operated with roughly 350 employees as of its last detailed public filings in 2022. May 2023: ADC Therapeutics licensed Zynlonta ex-US rights to Swedish Orphan Biovitrum, receiving $55 million upfront and tiered royalties, a move that sharpened its focus on the US commercial business and internal pipeline. The firm funds operations through product revenue, royalty agreements, and a $65 million royalty-backed loan tranche from Blue Owl executed in 2022. Unlike large-cap oncology players, ADC Therapeutics lacks a partnered megablockbuster or diversified modality base, making it a concentrated bet on a single technology class. ADC Therapeutics' structural distinctiveness comes from being the only NYSE-listed biotech built entirely around a single antibody-drug conjugate platform origin — a model that fuses Spirogen's academic chemistry legacy with direct US commercial infrastructure. That concentration amplifies both pipeline success and clinical setback risk, creating a binary profile that institutional crossover investors treat as a sector proxy for the modality, not a diversified oncology fund. ## Sectors - Biotechnology - Oncology ## People - Chris Martin — Chief Executive Officer ## Questions ### What does ADC Therapeutics' technology platform actually do? The firm's antibody-drug conjugates use pyrrolobenzodiazepine dimers — chemical warheads that bind to and cross-link tumor cell DNA, triggering cell death. Unlike earlier-generation chemotherapy linkers, PBD dimers can kill tumor cells that are not actively dividing. The antibody component targets specific surface receptors like CD19 on lymphoma cells, which the company claims reduces off-target toxicity compared to conventional chemo regimens. ### Who controls ADC Therapeutics — is there a concentrated owner or family behind it? No single family controls the firm. ADC Therapeutics is a widely held NYSE-listed company. Auven Therapeutics, the original private equity incubator, distributed shares to Auven's limited partners at the 2020 IPO. Institutional holders as of public filings include Redmile Group, Aviva Investors, and BNP Paribas affiliates, none with disclosed controlling stakes. ### What is the status of Zynlonta's full FDA approval? Zynlonta received accelerated FDA approval in April 2021 based on single-arm Phase 2 data. The confirmatory Phase 3 LOTIS-5 trial, comparing Zynlonta plus rituximab against standard chemo-immunotherapy in second-line diffuse large B-cell lymphoma, is the required post-marketing study. Results will determine whether the accelerated approval converts to full regulatory approval; the firm has guided for data in 2025. ### Does ADC Therapeutics license its technology to other drug developers? Only selectively, and not as a standalone licensing business. The Spirogen platform was originally a licensable warhead chemistry used by other biotechs, but since AstraZeneca's acquisition of Spirogen in 2013, third-party access narrowed. ADC Therapeutics' current pipeline is wholly owned, with partnerships structured as specific product rights transactions — like the Sobi Zynlonta deal — rather than broad platform licenses. ### How does ADC Therapeutics compare to Seagen, the larger ADC peer? Seagen operates at roughly 10x the commercial scale with four approved drugs and a marketing partnership with Takeda, plus a $43 billion acquisition by Pfizer announced in 2023. ADC Therapeutics is a single-product company with no pharma anchor partner for its US commercial business. The comparison is meaningfully one of scale, pipeline breadth, and balance-sheet strength — ADC is a mono-product ADC story where Seagen was the diversified platform. ## Related profiles - [KKR Real Estate Finance Trust](https://altss.com/profile/kkr-real-estate-finance-trust-inc) - [Sagimet Biosciences](https://altss.com/profile/sagimet-biosciences-inc) --- Last updated: 2026-07-09T00:46:52.550Z Canonical page: https://altss.com/profile/adc-therapeutics-sa Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology